Phase
Condition
Psoriasis And Psoriatic Disorders
Warts
Scalp Disorders
Treatment
Deucravacitinib
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasisinitiating deucravacitinib according to approved label in the European Union
The decision upon treatment with deucravacitinib must have been made beforeenrollment and independently of this non-interventional observational study
Patient is at least 18 years of age at the time of treatment decision
Patient provided written informed consent to participate in the study
Exclusion
Exclusion Criteria:
Any contraindications according to the approved deucravacitinib Summary of ProductCharacteristics
Prior treatment with deucravacitinib
Simultaneous participation in an interventional clinical trial formoderate-to-severe psoriasis
Study Design
Connect with a study center
Dermatologische Spezial- und Schwerpunktpraxis Selters
Selters, Rhineland-Palatinate
GermanySite Not Available
Company for Medical Study & Service Selters
Selters, 56242
GermanyActive - Recruiting
Local Institution - 0001
Selters, 56242
GermanySite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.